Intestinal Research

Original Articles

IBD

Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan: Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto; Intest Res 2026;24(1):95-102. Published online March 20, 2025; DOI: https://doi.org/10.5217/ir.2024.00187

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Tofacitinib and upadacitinib are small-molecule compounds that inhibit the Janus kinase pathway for the treatment of refractory ulcerative colitis. Only a few reports have compared the efficacy and safety of these 2 drugs in real-world practice. We aimed to show our real-world evidence of these drugs and compare the efficacy and safety profiles in the treatment of ulcerative colitis.
Methods
This study is a single-center retrospective analysis. Patients treated with tofacitinib or upadacitinib at our hospital between June 2018 and January 2024 who were monitored for 24 weeks were included. The primary outcome was steroid-free clinical remission at 24 weeks. Secondary outcomes were response and remission rates at each time point, time series changes in partial Mayo scores and laboratory results, treatment survival at 24 weeks, and the incidence of adverse events.
Results
A total of 68 patients treated with tofacitinib and 34 patients treated with upadacitinib were included. Steroid-free clinical remission rate at 24 weeks was significantly higher in upadacitinib-treated patients than in tofacitinibtreated patients (64.7% vs. 38.2%). The response rates in upadacitinib-treated patients exceeded 60% after 8 weeks of treatment through to 24 weeks, and the rates were higher than those in tofacitinib-treated patients. The incidences of adverse events were 79.4% in upadacitinib-treated patients and 38.2% in tofacitinib-treated patients. The most common adverse event was acne for upadacitinib.
Conclusions
Upadacitinib was more effective than tofacitinib in inducing remission in ulcerative colitis patients. The incidence of adverse events was significantly higher with upadacitinib than tofacitinib.

Citations

Citations to this article as recorded by

Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective
Shintaro Akiyama
Intestinal Research.2026; 24(2): 197. CrossRef
Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice
Javier P Gisbert, María Chaparro
Inflammatory Bowel Diseases.2026; 32(4): 775. CrossRef
Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha
Intestinal Research.2026; 24(1): 27. CrossRef
Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis
Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy
Inflammatory Bowel Diseases.2026;[Epub] CrossRef
Upadacitinib after tofacitinib in ulcerative colitis
Hyeon Jin Cho, Eun Soo Kim
Intestinal Research.2025; 23(3): 229. CrossRef
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Clara De Francesco, Nunzio Belluardo, Emiliano Giangreco, Maria Cappello, Roberto Ajovalasit, Filippo Mocciaro, Barbara Scrivo, Antonino Carlo Privitera, Maria Emanuela Distefano, Alessandro Vitello, Con
Digestive and Liver Disease.2025; 57(11): 2109. CrossRef
Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs
Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Successful treatment of tofacitinib-refractory scleritis associated with multiple systemic inflammatory diseases using upadacitinib
Kodai Yuge, Nobuyo Yawata, Kenichiro Asahara, Satoshi Yamana, Nobuyuki Ono, Koh-Hei Sonoda
Immunological Medicine.2025; : 1. CrossRef
Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis
Tareq Alsaleh, Abdul Mohammed, Aimen Farooq, Magda Elamin, Amr Akl, Karim Mohamed Yassin, Ahmed Elnaggar, Jennifer Seminerio
Inflammatory Intestinal Diseases.2025; 11(1): 29. CrossRef

9,411 View
589 Download
9 Web of Science
9 Crossref

IBD

Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study: Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto; Intest Res 2024;22(3):369-377. Published online July 16, 2024; DOI: https://doi.org/10.5217/ir.2023.00194

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of its short-term efficacy and safety profiles have already been published, reports of long-term real-world data have been limited. We aimed to show our 3-year evidence on the clinical use of tofacitinib for the treatment of UC, focusing on its efficacy and safety profiles.
Methods
A retrospective observational study was conducted on patients who started tofacitinib for active refractory UC at our hospital. The primary outcome was the retention rate until 156 weeks after initiating tofacitinib. The secondary outcomes were short-term efficacy at 4, 8, and 12 weeks; long-term efficacy at 52, 104, and 156 weeks; prognostic factors related to the cumulative retention rate; loss of response; and safety profile, including adverse events.
Results
Forty-six patients who were able to be monitored for up to 156 weeks after tofacitinib initiation, were enrolled in this study. Continuation of tofacitinib was possible until 156 weeks in 54.3%, with > 50% response rates and > 40% remission rates. Among patients in whom response or remission was achieved and tofacitinib was deescalated after 8 weeks of induction treatment, 54.3% experienced relapse but were successfully rescued by and retained on reinduction treatment, except for 1 patient. No serious AEs were observed in the study.
Conclusions
Tofacitinib is effective and safe as long-term treatment in a refractory cohort of UC patients in real-world clinical practice.

Citations

Citations to this article as recorded by

Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto
Intestinal Research.2026; 24(1): 95. CrossRef
Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha
Intestinal Research.2026; 24(1): 27. CrossRef
The Evolving Landscape of Advanced Therapies in Inflammatory Bowel Disease: Current Evidence and Emerging Targets
Daniele Balducci, Marta Mosca, Sabrina Monaco, Susanna Faenza, Stefano Fabiani, Fabio Cortellini, Nicola Cesaro, Gianpiero Stefanelli, Salvatore Paba, Maddalena Pecchini, Michele Montori, Marco Valvano
Gastrointestinal Disorders.2026; 8(1): 13. CrossRef
In which patients with ulcerative colitis would filgotinib be effective?
Jihye Park
Intestinal Research.2025; 23(1): 1. CrossRef
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
Rogério Serafim Parra, Renata de Sá Brito Fróes, Daniela Oliveira Magro, Sandro da Costa Ferreira, Munique Kurtz de Mello, Matheus Freitas Cardoso de Azevedo, Aderson Omar Mourão Cintra Damião, Alexandre de Sousa Carlos, Luísa Leite Barros, Maria Luiza Qu
BMC Gastroenterology.2025;[Epub] CrossRef
State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review
Yunseok Choi, Suhyun Lee, Hyeon Ji Kim, Taemin Park, Won Gun Kwack, Seungwon Yang, Eun Kyoung Chung
Pharmaceuticals.2025; 18(5): 740. CrossRef
Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib
Arshdeep Singh, Arshia Bhardwaj, Devanshi Jain, Riya Sharma, Dharmatma Singh, Ramit Mahajan, Kirandeep Kaur, Aminder Singh, Vikram Narang, Harpreet Kaur, Manavjot Singh, Pritish Gupta, Tanisha Sehgal, Vandana Midha, Ajit Sood
Indian Journal of Gastroenterology.2025;[Epub] CrossRef
Exploring the Factors Associated With the Discontinuation of Tofacitinib in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study
Li‐Huei Chiang, Chia‐Ling Yu, Tzu‐Cheng Tsai, Yao‐Fan Fang
International Journal of Rheumatic Diseases.2025;[Epub] CrossRef
Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease
Anja Bizjak, Boris Gole, Gregor Jezernik, Uroš Potočnik, Mario Gorenjak
Genes.2025; 16(8): 908. CrossRef
Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs
Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Three Janus kinase inhibitors in ulcerative colitis: is upadacitinib taking the lead?
Yoon Suk Jung
Intestinal Research.2025; 23(4): 394. CrossRef
Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective
Shintaro Akiyama
Intestinal Research.2025;[Epub] CrossRef
Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics
Themba Mudege, Jonathan Soldera
World Journal of Meta-Analysis.2025;[Epub] CrossRef
Drug-induced liver injury in inflammatory bowel disease: Challenges in diagnosis and monitoring
Arshdeep Singh, Arshia Bhardwaj, Harmeet Kaur, Ashutosh Bawa, Vandana Midha, Ajit Sood
World Journal of Hepatology.2025;[Epub] CrossRef

10,076 View
233 Download
13 Web of Science
14 Crossref

IBD

Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy: Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto; Intest Res 2024;22(1):65-74. Published online November 9, 2023; DOI: https://doi.org/10.5217/ir.2023.00092

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Endoscopic activity confirmed by enteroscopy is associated with poor clinical outcome in Crohn’s disease (CD). We investigated which of the existing biomarkers best reflects endoscopic activity in CD patients including the small bowel, and whether their combined use can improve accuracy.
Methods
One hundred and four consecutive patients with ileal and ileocolonic type CD who underwent balloon-assisted enteroscopy (BAE) from October 2021 to August 2022 were enrolled, with clinical and laboratory data prospectively collected and analyzed.
Results
Hemoglobin, platelet count, C-reactive protein, leucine-rich alpha-2 glycoprotein (LRG), fecal calprotectin, and fecal hemoglobin all showed significant difference in those with ulcers found on BAE. LRG and fecal calprotectin showed the highest areas under the curve (0.841 and 0.853) for detecting ulcers. LRG showed a sensitivity of 78% and specificity of 80% at a cutoff value of 13 μg/mL, whereas fecal calprotectin showed a sensitivity of 91% and specificity of 67% at a cutoff value of 151 μg/g. Dual positivity for LRG and fecal calprotectin, as well as LRG and fecal hemoglobin, both predicted ulcers with an improved specificity of 92% and 100%. A positive LRG or fecal calprotectin/hemoglobin showed an improved sensitivity of 96% and 91%. Positivity for LRG and either of the fecal biomarkers was associated with increased risk of hospitalization, surgery, and relapse.
Conclusions
The biomarkers LRG, fecal calprotectin, and fecal hemoglobin can serve as noninvasive and accurate tools for assessing activity in CD patients confirmed by BAE, especially when used in combination.

Citations

Citations to this article as recorded by

Leucine-rich alpha-2 glycoprotein as a blood biomarker in inflammatory bowel disease: clinical implications and future perspectives
Takayuki Yamamoto
Expert Review of Gastroenterology & Hepatology.2026; 20(2): 147. CrossRef
Leucine-rich alpha-2 glycoprotein in combination with C-reactive protein for predicting endoscopic activity in Crohn’s disease: a single-centre, cross-sectional study
Yoshiaki Takada, Hiroki Kiyohara, Yohei Mikami, Masataka Taguri, Ryoya Sakakibara, Yasuhiro Aoki, Kosaku Nanki, Takaaki Kawaguchi, Yusuke Yoshimatsu, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Naoki Hosoe, Haruhiko Ogata, Motohiko Kato, Yasushi
Annals of Medicine.2025;[Epub] CrossRef
Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
Masashi Ohno, Atsushi Nishida, Akinori Otsuki, Yoshihiro Yokota, Takayuki Imai, Shigeki Bamba, Osamu Inatomi
World Journal of Gastrointestinal Endoscopy.2025;[Epub] CrossRef
The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis
Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Behrad Saeedian, Tannaz Bagheri, Abdulrahman Ismaiel, Satohiro Matsumoto, Nastaran Babajani
European Journal of Gastroenterology & Hepatology.2025; 37(8): 891. CrossRef
Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn’s disease activity in the small bowel
Muneyori Okita, Kento Takenaka, Fumihito Hirai, Shinya Ashizuka, Hideki Iijima, Shigeki Bamba, Toshimitsu Fujii, Kenji Watanabe, Yosuke Shimodaira, Hisashi Shiga, Sakiko Hiraoka, Toshihiro Inokuchi, Takeshi Yamamura, Ryo Emoto, Shigeyuki Matsui
Journal of Gastroenterology.2025; 60(5): 573. CrossRef
Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn’s disease during biological remission
Naohiro Nakamura, Yusuke Honzawa, Yuka Ito, Yasuki Sano, Naoto Yagi, Sanshiro Kobayashi, Mamiko Aoi, Takashi Tomiyama, Tomomitsu Tahara, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma
Intestinal Research.2025; 23(2): 170. CrossRef
Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers
Kensuke Takei, Toshihiro Inokuchi, Sakiko Hiraoka, Mikako Ishiguro, Junki Toyosawa, Yuki Aoyama, Shoko Igawa, Keiko Takeuchi, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Seiji Kawano, Toshiharu Mitsuhashi, Motoyuki Otsuka
BMC Gastroenterology.2025;[Epub] CrossRef
Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study
Natsuki Ishida, Satoshi Tamura, Tomohiro Takebe, Kenichi Takahashi, Yusuke Asai, Tomoharu Matsuura, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Takanori Yamada, Satoshi Osawa, Ken Sugimoto
Inflammatory Bowel Diseases.2025; 31(9): 2420. CrossRef
Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
Jihye Park
Intestinal Research.2024; 22(1): 1. CrossRef
Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn’s disease small bowel lesion in capsule endoscopy
Teppei Omori, Miki Koroku, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige
Intestinal Research.2024; 22(4): 464. CrossRef
Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease
Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kiz
Scientific Reports.2024;[Epub] CrossRef

8,634 View
339 Download
12 Web of Science
11 Crossref

Brief Communication

IBD

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis: Hiromichi Shimizu, Toshimitsu Fujii, Shuji Hibiya, Maiko Motobayashi, Kohei Suzuki, Kento Takenaka, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe; Intest Res 2021;19(1):115-118. Published online June 11, 2020; DOI: https://doi.org/10.5217/ir.2020.00030

PDF Supplementary Material PubReader ePub

Citations

Citations to this article as recorded by

Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto
Intestinal Research.2026; 24(1): 95. CrossRef
Tofacitinib safety in inflammatory bowel disease: a disproportionality analysis of the FDA adverse event reporting system
Suqi Zeng, Sihan Zhang, Jianxuan Sun, Junjie Chen
Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef
Inflammatory bowel disease therapeutics: a bibliometric analysis of tofacitinib research in ulcerative colitis
Jianping Zhou, Yuting Xi, Yaping Zhang, Rui Zhang, Hao Fu, Ce Zhou
Frontiers in Pharmacology.2025;[Epub] CrossRef
Association between inflammatory bowel disease, current therapies, and cardiovascular events: a review and meta-analysis of data from 2.2 million individuals
David-Raj Thomas, Gavin Huangfu, Fiona Yeaman, Sara Sukudom, Nick S R Lan, Girish Dwivedi, Lena Thin
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease
Anja Bizjak, Boris Gole, Gregor Jezernik, Uroš Potočnik, Mario Gorenjak
Genes.2025; 16(8): 908. CrossRef
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study
Sophie Vieujean, David Laharie, Anthony Buisson, Xavier Roblin, Mathurin Fumery, Stephane Nancey, Pauline Wils, Romain Altwegg, Laurence Seidel, Bénédicte Caron, Laurent Peyrin-Biroulet
Digestive and Liver Disease.2024; 56(4): 613. CrossRef
Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea
Young-Eun Kim, Ye-Jee Kim, Dae Hyun Jeong, Seonok Kim, Min Jee Kim, Hyeon Hwa Kim, Kyung-Wook Jo, Sang Hyoung Park, Seokchan Hong
Seminars in Arthritis and Rheumatism.2024; 65: 152362. CrossRef
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Pablo A. Olivera, Axel Dignass, Marla C. Dubinsky, Giovanni Peretto, Paulo G. Kotze, Iris Dotan, Taku Kobayashi, Subrata Ghosh, Fernando Magro, Jose Rocha Faria-Neto, Britta Siegmund, Silvio Danese, Laurent Peyrin-Biroulet
Digestive and Liver Disease.2024; 56(8): 1270. CrossRef
Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto
Intestinal Research.2024; 22(3): 369. CrossRef
Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study
Hyuk Yoon, Byong Duk Ye, Sang-Bum Kang, Kang-Moon Lee, Chang Hwan Choi, Joo-young Jo, Juwon Woo, Jae Hee Cheon
BMC Gastroenterology.2024;[Epub] CrossRef
Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies
Chien-Hung Lin, Wen-Sheng Liu, Chuan Wan, Hsin-Hui Wang
BMJ Open Gastroenterology.2024; 11(1): e001347. CrossRef
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
María Chaparro, Diana Acosta, Cristina Rodríguez, Francisco Mesonero, Miren Vicuña, Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Álvaro Hernández Martínez, Maite Arroyo, Isabel Vera, Alexandra Ruiz-Cerulla, Beatriz Sicilia, M. José Cabello Tapia, Ca
American Journal of Gastroenterology.2023; 118(7): 1237. CrossRef
Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, Stephane Zuily, Silvio Danese, Laurent Peyrin‐Biroulet
Alimentary Pharmacology & Therapeutics.2023; 57(11): 1231. CrossRef
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja
Expert Review of Gastroenterology & Hepatology.2022; 16(8): 737. CrossRef
Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef
Review article: guide to tofacitinib dosing in patients with ulcerative colitis
Peter M. Irving, Yvette Leung, Marla C. Dubinsky
Alimentary Pharmacology & Therapeutics.2022; 56(7): 1131. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
Effectiveness and Safety of Tofacitinib for Ulcerative Colitis
Vikas Taneja, Mohammed El-Dallal, Zadid Haq, Kartikeya Tripathi, Hannah K. Systrom, Linda F. Wang, Hyder Said, Paul A. Bain, Youlian Zhou, Joseph D. Feuerstein
Journal of Clinical Gastroenterology.2022; 56(10): e323. CrossRef
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
Laura A. Lucaciu, Nathan Constantine-Cooke, Nikolas Plevris, Spyros Siakavellas, Lauranne A.A.P. Derikx, Gareth-Rhys Jones, Charles W. Lees
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef

9,191 View
267 Download
23 Web of Science
20 Crossref

Review

IBD

Stem cell-based therapy for inflammatory bowel disease: Hiromichi Shimizu, Kohei Suzuki, Mamoru Watanabe, Ryuichi Okamoto; Intest Res 2019;17(3):311-316. Published online July 25, 2019; DOI: https://doi.org/10.5217/ir.2019.00043

Abstract PDF PubReader ePub

Inflammatory bowel disease (IBD) is an idiopathic, multi-etiological disease characterized by inflammation and mucosal destruction of the gastrointestinal tract. Despite the remarkable advance in immunomodulating therapies, there still remains a certain population of patients who are refractory to conventional as well as biologic therapies and fail to achieve mucosal healing. To improve the prognosis of those patients, at least 2 types of stem cells have been tested for their potential therapeutic use. Transplantation of hematopoietic stem cells or mesenchymal stem cells have been tested in several clinical studies, but their beneficial effect still remains controversial. In this review, we would like to overview the recent clinical challenges of stem cell-based therapies in IBD and also introduce our new therapeutic plan of intestinal stem cell transplantation for IBD, based on our ex vivo intestinal organoid culture technique.

Citations

Citations to this article as recorded by

Mesenchymal stem cell-derived exosomes as a plausible immunomodulatory therapeutic tool for inflammatory diseases
Muhammad Zubair, Fatma A. Abouelnazar, Muhammad Asad Iqbal, Jingyun Pan, Xuwen Zheng, Tao Chen, Wenming Shen, Jinnan Yin, Yongmin Yan, Pengjun Liu, Fei Mao, Ying Chu
Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Myths and Realities about the Private Sector Stem Cell Industry in Malaysia
Kean Chang Phang, Mohammad Firdaus Bin Abdul Aziz
Asian Bioethics Review.2025; 17(4): 729. CrossRef
Optimizing Wnt activation in fetal calf serum (FCS)-free organoid expansion media
Esther J. M. Liefting, Jeffrey J. Bajramovic
Frontiers in Toxicology.2025;[Epub] CrossRef
From bench to bedside: the role of gastrointestinal stem cells in health and disease
Xiaopeng Bai, Eikichi Ihara, Yoshimasa Tanaka, Yosuke Minoda, Masafumi Wada, Yoshitaka Hata, Mitsuru Esaki, Haruei Ogino, Takatoshi Chinen, Yoshihiro Ogawa
Inflammation and Regeneration.2025;[Epub] CrossRef
Cell-derived vesicles extruded from adipose mesenchymal stem cells attenuate intestinal inflammation and augment epithelial regeneration in a colitis model
Min Kyoung Jo, Hyeon-Jeong Jeon, So Hui Kim, Hye Sun Lee, Seong-Eun Kim, Sung-Ae Jung, Hui-Chong Lau, Sung-Soo Park, Seung Wook Oh, Chang Mo Moon
Nanoscale.2025; 17(47): 27337. CrossRef
The nasal basal cell population shifts toward a diseased phenotype with impaired barrier formation capacity in allergic rhinitis
Emma Ruysseveldt, Brecht Steelant, Tine Wils, Jonathan Cremer, Dominique M.A. Bullens, Peter W. Hellings, Katleen Martens
Journal of Allergy and Clinical Immunology.2024; 154(3): 631. CrossRef
Cellular Plasticity in Gut and Liver Regeneration
Minwook Kim, Yoojeong Park, You Sun Kim, Sungjin Ko
Gut and Liver.2024; 18(6): 949. CrossRef
Revolutionizing medicine: recent developments and future prospects in stem-cell therapy
Bashdar M. Hussen, Mohammad Taheri, Raya Kh. Yashooa, Gaylany H. Abdullah, Snur R. Abdullah, Ramiar Kamal Kheder, Suhad A. Mustafa
International Journal of Surgery.2024; 110(12): 8002. CrossRef
Nigakinone alleviates DSS‐induced experimental colitis via regulating bile acid profile and FXR/NLRP3 signaling pathways
Fangle Liu, Yufeng Yao, Qian Wang, Fengxue Zhang, Meiqi Wang, Chenchen Zhu, Chaozhan Lin
Phytotherapy Research.2023; 37(1): 15. CrossRef
TNFα Induces LGR5+ Stem Cell Dysfunction In Patients With Crohn’s Disease
Chansu Lee, Minae An, Je-Gun Joung, Woong-Yang Park, Dong Kyung Chang, Young-Ho Kim, Sung Noh Hong
Cellular and Molecular Gastroenterology and Hepatology.2022; 13(3): 789. CrossRef
Bovine colostrum derived-exosomes prevent dextran sulfate sodium-induced intestinal colitis via suppression of inflammation and oxidative stress
Geonhee Han, Haeun Cho, Hyosuk Kim, Yeongji Jang, Hochung Jang, Da Eun Kim, Eun Sun Kim, Eun Hye Kim, Kwang Yeon Hwang, Kwangmeyung Kim, Yoosoo Yang, Sun Hwa Kim
Biomaterials Science.2022; 10(8): 2076. CrossRef
The therapeutic potential of stem cell-derived exosomes in the ulcerative colitis and colorectal cancer
Gang Guo, Zhaobang Tan, Yaping Liu, Feiyu Shi, Junjun She
Stem Cell Research & Therapy.2022;[Epub] CrossRef
Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases
Zhengping Che, Ziyu Ye, Xueying Zhang, Bihua Lin, Weiqing Yang, Yanfang Liang, Jincheng Zeng
Frontiers in Immunology.2022;[Epub] CrossRef
Mechanotransduction through adhesion molecules: Emerging roles in regulating the stem cell niche
Ryan Lim, Avinanda Banerjee, Ritusree Biswas, Anana Nandakumar Chari, Srikala Raghavan
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Clinical applications and optimization of patient-derived organoids in intestinal diseases
Tae Il Kim
Organoid.2022; 2: e22. CrossRef
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Jinsha Liu, Joey Paolo Ting, Shams Al-Azzam, Yun Ding, Sepideh Afshar
International Journal of Molecular Sciences.2021; 22(6): 2805. CrossRef
Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn’s disease: a retrospective observational stud
Min Young Park, Yong Sik Yoon, Jong Lyul Lee, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Chang Sik Yu
Stem Cell Research & Therapy.2021;[Epub] CrossRef
Current Trends and Research Topics Regarding Intestinal Organoids: An Overview Based on Bibliometrics
Meng-Meng Zhang, Ke-Lu Yang, Yan-Cheng Cui, Yu-Shi Zhou, Hao-Ran Zhang, Quan Wang, Ying-Jiang Ye, Shan Wang, Ke-Wei Jiang
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
The Potential of Vitamin D3 to Repaired Mucosal Injury in Dextran Sulfate Sodium Induced Acute Colitis in Mice
Satrio Wibowo, Krisni Subandiyah, Kusworini Handono, Sri Poeranto
Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 931. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
Mutual regulation between butyrate and hypoxia‐inducible factor‐1α in epithelial cell promotes expression of tight junction proteins
Jiuheng Yin, Chao Zhou, Kunqiu Yang, Yanbei Ren, Yuan Qiu, Pengyuan Xu, Weidong Xiao, Hua Yang
Cell Biology International.2020; 44(6): 1405. CrossRef
Letter: off‐label use of hyperbaric oxygen therapy in inflammatory bowel disease—Authors’ reply
Melek Simsek, Nanne K. H. de Boer
Alimentary Pharmacology & Therapeutics.2020; 52(1): 216. CrossRef
The Role of Immune and Epithelial Stem Cells in Inflammatory Bowel Disease Therapy
Agata Binienda, Sylwia Ziolkowska, Ingvild H. Hauge, Maciej Salaga
Current Drug Targets.2020; 21(14): 1405. CrossRef

12,339 View
277 Download
24 Web of Science
23 Crossref

First
Prev
Page of 1
Next
Last

Search